30 Prognostic analysis of the early lymphocyte recovery in patients (PTS) with advanced breast cancer receiving high-dose chemotherapy (HDC) with an autologous hematopoietic progenitor cell transplant  by Nieto, Y. et al.
Oral Presentations 
SOLID TUMORS 
28 
LONG-TERM ANALYSIS OF HIGH-RISK PRIMARY BREAST CANCER 
PATIENTS ENROLLED IN PROSPECTIVE TRIALS OF HIGH-DOSE 
CHEMOTHERAPY (HDC) AND AUTOLOGOUS HEMATOPOIETIC PROG- 
ENITOR CELL TRANSPLANT (AHPCT) 
Nieto, Y.l. Shpall, E.,~d; Bea'*v,aJ1, S.I. 7; Mc,%,e,,,ey, P.A. s; .7o,es ' 
R.B. 2 1. UJl, ivevsity of Colorado, De~z,e*', CO; 2. M.D. A~Mez'~v, G,z 
cev Ce~tev, Hoztsto*~, T k: 
Between 1990 and 2001, 265 pts were treated at the University 
of Colorado in prospective HDC trials for stage II/III breast can- 
cer involving 4-9, >10 + nodes, or inflammatory disease (IBC). Pts 
received standard chemotherapy, followed by HDC (cyclophos- 
phamide 5, 625, cisplatin 165, and BCNU 600 mg/m 2) with 
AHPCT, radiotherapy, and tamo~fen x 5 yrs if estrogen/proges- 
terone receptor (ER/PR) +. Outcome There were 13 (4.9%) 
HDC-related deaths, with no age effect (p=0.3). 2 pts developed 
acute myelogenous leukemia t >5 yrs post-HDC. At median F/U 
of survivors of 7 (1-11) yrs, the relapse-free (RFS) and overall sur- 
vival (OS) rates are 66.7% (95% CI, 61-72%) and 70.2% (65- 
76%), respectively. Median RFS and OS times have not been 
reached. Actuarial RFS/OS rates are 68%/72% at 5 yrs, and 
65%/67% at 10 yrs. No differences in RFS (p=0.3) or OS (p=0.3) 
were detected among the 3 groups (table). Median time to relapse 
was 14 months. Of the 74 relapses, 47 (63.5%) occurred in the 
first 2 yrs after HDC (1st yr: 31, 2nd yr: 16), 22 (29.7%) in yrs 2- 
5, and 5 (6.7%) after the 5th yr. Prognos6c analyses 1) No effect 
of age on relapse was detected (p=0.6). 2) A multivariable analysis 
of a subset of 175 pts treated through 7/97 resulted in the t~)llow- 
ing model: Score = [tumor size (can) x 0.l 5] + [nodal ratio x 3.05] - 
[ER/PR x 1.1] (Nodal ratio = # + nodes /# dissected nodes), 
(ER/PR -0 if -, =1 if +). Scores >2.41 and <2.41 confer >50% and 
<20% relapse risks, respectively (p<0.00001). The score was exter- 
nally validated (Duke). 3) At current minimum F/U >5 yrs, the 
score remains significant in our first subset(p-0.0001). It was 
prospectively validated in 77 pts treated since 7/97 (median FlU 3 
yrs) (p=0.003). 4) HER2 was another independent predictor 
(p=0.0003). 5) A final model combines the score and HER2 
(p<0.0000I): Low risk (low score + HER2 -) (N-91): 87% DFS; 
Intermediate risk (low score + HER2+) (N=5 I): 59% DFS; High 
risk (high score, any HER2) (N=51): 49% DFS. Conclusions: 1) 
Our encouraging long-term results, with few relapses een after 5 
yrs, indicate the need for mature FlU of the randomized trials. 2) 
hnportant prognostic factors can be identified that may help inter- 
pret the randomized trials, as well as select pts for testing of novel 
HDC-based strategies. 
4-9+ nodes 
> 10+ nodes 
N 
93 74.2%, 
120 64.1% 65.8% 
IBC 52 63.4% 69.2% 
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A MULTICENTER STUDY OF ALLOGENEIC STEM CELL TRANSPLANTA- 
TION (ASCT) FOR ADVANCED SOLID TUMORS 
Blaise, D.P. 1; B~gj ' if.e; Fa,cbe'l", C.S; Micballet, M. ;; BoiJ'o,, .7.s; Cah,, 
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Fraz~ce; 5. CHU flea, Mi,2joz, BesaJ~fo,z, Fzv,ee; 6. CHU Cimiez, 
Nice, Flvllce; 7. CHU MichaloT~, Grelzoble, FTza~zce, 8. CHU AJ~gers, 
Angers, F'raJzce. 
Despite progress in chemotherapy, a large number of patients 
suffering from ST always die from cancer evolution. Conversely 
ASCT has shown its potential  to eradicate mal ig-nant 
hemopathies by immune control. On these bases we aimed to 
establish if ASCT may represent a potential treatment in ST with 
acceptable toxicity in a multicenter program. 46 consecutive 
patients (age: 43(18 60)) with refractory ST (RCC:16; Breast:10; 
Ovarian:6; Melanoma:6; others:8) (Prog disease (PD)/stable dis- 
ease (SD):32/14) were included from 96/12 to 01/11 in this study 
to be grafted from a HLA identical sibling in 8 centers. Standard 
ASCT with myeloablative conditioning regimen (MAR) and BMT 
was used in the 6 initial patients. Then MAR was switched to 
reduced intensity regimen (RIR) is combining fludara-bin (180 
rag/m2), ATG (1 to 4 days) and reduced Busulfan (8 mg/kg) in the 
40 following pa-tients and followed by allo graft (BMT/PBSCT: 
16/14). In this setting of advanced iseases, we found that RfR 
offered low TRiM (5% (95% CI: 0-12%)). An antimmoral effect 
could be docmnented (Objective response (PR+CR) (OR) - 18% 
(95% CI:6%-30%)) (RCC:2; breast:2; ovarian:3; melanoma:l) at a 
median of 90 days (30-190) post transplant and was associated 
with a higher 12 month smwival (OR (N=8) vs. no OR (N=38) 75 
% vs. 12 % p=0.001). Patients with SD prior to transplant pre- 
sented a higher OR rate (50 % vs. 3 %; p=0.0006): this was the 
only factor statistically predicting OR (odd ratio = 11.4 (95% CI: 
1.4-92); p=0.02) in a Cox analysis model. Disease status at trans- 
plant and cGVHD significativc]y influenced ly survival in a land- 
mark analysis tarting on day 100 (SD/PD: 56% vs. 21% (p=0.03); 
cGVHD/No: q3% vs. 6% (p=0.02)). These 2 factors remain inde- 
pendent in a nmltivariate analysis (odd ratio (95% CI): cGVHD: 
3.5 (1.4-8.5), p=0.007; Stable disease: 3.4(I.3-8.9), p=0.02). In this 
perspective, PBSCT seems to be the best choice offering a higher 
rate of cGVItD (BMT vs. PSCT: 14% vs. 76 %; p=0.0006) with 
out an increased mortality. Results show that such a RIR followed 
by allogeneic PBSCT represents a valid option to investigate allo 
geneic immunotherapy in various subsets of solid tumors and 
deserves fl~rther studies 
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PROGNOSTIC ANALYSIS OF THE EARLY LYMPHOCYTE RECOVERY IN 
PATIENTS (PTS) WITH ADVANCED BREAST CANCER RECEIVING 
HIGH-DOSE CHEMOTHERAPY (HDC) WITH AN AUTOLOGOUS 
HEMATOPOIETIC PROGENITOR CELL TRANSPLANT 
Nieto, y.l; Jo~es, R.Bd; BeaJv, a,, S.I.S; 3dcNiece, I.Kd: McSzveelley, 
P.A.I; Shpa//, E.ff. 2 I. UMvevsity of Co/oTwto, De~zvev, CO; 2. MD 
AJll/evsoJl Omcer CeTltev, Ho,stoT~, TX. 
PURPOSE: To evaluate the correlation f the early lymphocyte 
recovery, with outcome in pts with high-risk primary breast cancer 
(HRPBC) and metastatic breast cancer (MBC) receiving HDC. 
PAT IENTS AND METHODS:  We analyzed the prognostic 
effect of the absolute lymphocyte count (ALC) on day +15 post- 
transplant in pts enrolled between 1990-200l in prospective trials 
of HDC (cyclophosphamide/cisplatin/BCNU) at the University of 
Colorado. RESULTS: 478 pts (265 HRPBC, 213 MBC) were 
evaluated at median follow up of 6 (1-11) years. The disease-free 
survival (DFS) and overall survival (OS) rates were 66% and 70%, 
respectively, in the HRPBC group, and 22% and 37%, respective- 
ly, in MBC pts. D+15 ALC was higher in I IRPBC than in MBC 
pts (930 vs. 500/mm 3, p=0.01). D+15 ALC did not correlate with 
age (p=0.8) or with the graft total nucleated cell dose (p=0.7). A 
very weak correlation was detected between D+15 ALC and the 
CD34+ cell dose (r2=0.06, p=0.005). D+15 ALC correlated with 
DFS (p-0.007) and OS (p-0.03) in MBC pts (table). In contrast, it 
was not associated with DFS (p=0.5) or OS (p=0.8) in HRPBC. 
The prognostic ffect of ALC in MBC was observed in pts receiv- 
ing peripheral-blood progenitor cells (N=137) (p=0.04), but not 
bone marrow (N-43) (p=0.8). Likewise, an effect from D+15 ALC 
,was seen in MBC pts receiving an unselected (N-134, p=0.04), but 
not a CD34-selected graft (N=79, p=0.8). In multivariate analyses, 
a high D+15 ALC was an independent protective factor in MBC, 
both for DFS, with a hazard ratio (HR) of 0.65 (p=0.02), and for 
OS (HR:0.7, p=0.04). These analyses included other variables also 
associated with outcome in univariate analyses of our MBC group: 
disease stares at transplant, # metastatic sites, radiotherapy deliv- 
ery, specific organ involved, primary a~llary nodal status, primary 
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inflammatory disease, HER2, hormone receptors, tumor grade, 
previous adjuvant chemotherapy, and prior anthracyclines. CON- 
CLUSIONS: Early lymphocyte recovery is an independent out- 
come predictor after HDC in MBC pts receiving a graft with a 
high T-cell content. These observations support the role for the 
immune system in tumor control after transplant, and suggest that 
pre- or post-HDC inmmne strategies targeting post-transplant 
residual disease may prove worthwhile. 
MBC pts Median DFS Median OS % DFS % OS 
Low ALC (_<500/mm 3) 1 yr 2.5 yrs 20% 29% 
High ALC (>500/ram 3 ) 2.3 yrs 4 yrs 33% 42% 
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BONE MARROW DERIVED HESENCHYMAL STEH CELLS : IMPACT ON 
NEOINTESTINAL ENGINEERING 
Gm~dia, C.; Defavia, W.; Smztiago, S.; Tryopl, o~mpoulos, P.; Ruiz, P.; 
Tzakis, A.; Kleiner, G. U*ziversity of 3/fiami School of MediciJ~e, 
Mia~ni, FL. 
The utilization of bone marrow derived stem cells in tissue 
regeneration and repair is progressing at a dramatic pace. Mes- 
enchymal stem cells are bone marrow derived cells that have been 
utilized to generate bone, cardiac and neuronal tissue. Neointesti- 
nal engineering from intestinal epithelial organoid units (IEOU) 
may be a potential alternative therapy to solve the problems of 
acute organ shortage and rejection in intestinal transplantation. 
The use of MSCs in tissue engineering studies has not been well 
described. We designed a protocol to study the potentiality of 
enteric stem cells resident in the intestinal c~Tpt to differentiate 
into intestinal epithelium. The morphological development in the 
neointestine that occurred at the site of IEOU was studied. 
Neonatal DA rats were used to isolate IEOU by collagenase-dis- 
pase digestion. Organoids (100-100,000) were seeded on 
polyglactin polymer and iluplanted into the omentum or the peri- 
toneal wall of an adult syngeneic animal. IEOU developed into 
neointestinal units. [n as early as three weeks, neointestine was 
demonstrated in 40% of peritoneal implants. As low as 500 IEOU 
resulted in 50% implants positive for neointestinal development 
including intestinal villi, goblet, and crypts. Co-culture of lnes- 
enchymal stem eels and IEOU in a trans-well system resulted in 
morphological changes of the MSCs. Four distinctive cytomor- 
phologies were evident on (lay five of cultre. MSCs in the absence 
of [EOU remained predominantly fibroblasts. The results suggest 
that non-hematopoietic stem cells may be usefill in tissue engi- 
neering. 
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ALDEHYDE DEHYDROGENASE IS EXPRESSED BY PRIMITIVE CD34 + 
HEMATOPOIETIC PROGENITORS 
Storms, R,I,V.s; Snf/'ord, RU; ColviJ1, O.t; Rice, H.~; Smith, C.A. ~ 
1. Depm~ment of 3/iedM~ze, Duke Universi O, 3/lediazl Center, D~trham, 
NC; 2. Mq~tt Cancer Center, Tnmpa, FL. 
Hematopoietic progenitors express aldehyde dehydrogenase 
(ALDH) (PNAS 96:0118, 1999). Cells with low orthogonal light 
scatter and high expression of ALDH (SSC 1° ALDH t'F) were iso- 
lated from umbilical cord blood (UCB) stained with a fluorescent 
substrate for ALDH (BODIPY-aminoacetaldehyde, BAAA). In 
the studies below the SSC 1° ALDH b~ ftaction represented 0.98 _+ 
0.03% of the UCB and were 73.3 + 0.6% CD34 +. These repre- 
sented 46.6 + 0.5% of the total CD34 + UCB cells. We now com- 
pare the deveIopmental potential of CD3@ cells ffactionated on 
the basis of their expression of ALDH. In 5 week long-term cul- 
tures (LTC) on AFF024 stroma, the ALDH h~ CD34 + cells con- 
tained 1.75-fold greater LTC than bulk CD34" UCB cells (196 + 
50 CFU/1000 cells versus 110 -+ 32 CFU/I000 cells, respectively, 
n=4). The ALDH~eg CD34 + fraction contained few LTC (21 -+ 14 
CFU/1000 cells). When cultured on AFT024 stroma with Kit lig- 
and (KL), Flt3 ligand (Flt3L) and IL-7 (see Punzel et al. Blood 
93:3750, 1999) all of the CD34 + cell fractions reproducibly gave 
rise to both lymphoid (CD56 +) and myeloid (CD13/CD15 +) prog- 
eny. The generation of CD56 + progeny was enhanced with the 
addition of ILl5. After 4 weeks in culture on AFF024 with KL, 
Flt3L and IL7, the ALDH t'~ CD34 + cells expanded only slightly 
more than the bulk CD34 + cells (3300 _+ I000-fold vs. 2700 _+ 800- 
fold, respectively, n=3). However the secondary LTC content of 
cultures initiated with ALDH br CD34 + UCB remained approxi- 
mately twice that of bulk CD34 + cultures. Cultures initiated with 
ALDHneg CI)34 + cells expanded only I050 _+ 140-fold and con- 
rained few secondary LTC. To monitor transplantable c lls the 
NOD/SC[D model was employed. Multilineage hematopoietic 
engraftment was docmnented in 8 of 10 NOD/SCID mice trans- 
planted with 3000 SSC l'' ALDH b~ UCB cells (median 3.9%, range 
0.2 - 20.8%) and can be achieved with as few as 300 ALDH b~ 
CD34 + cells. These studies indicate that ALDH b~ cells are more 
efficient han bulk CD34 + cells in this modeh In total, these stud 
ies indicate that the ALDH hr CD34 + UCB are enriched for primi- 
tive, lympho myeloid progenitors. 
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THE ROLE OF B-CATENIN IN CHRONIC MYELOGENOUS LEUKEMIC 
COMPARED WITH NORMAL HUMAN HEMATOPOIETIC STEM CELL 
AND HYELOID PROGENITOR EXPANSION 
ffamiesmz, C.H.; Ailles, L.E.; MuijtjelT,r, M.; Weissman, I.L. Hematol- 
ogy~Pathology, StaJ~bvcl University. 
B-catenin, an important do'amstream regnlator of Wnt  sigualing, 
is frequently mutated in epithelial malignancies and plays a key role 
in hematopoietic stem cell self-renewal (T. Reya et al, submitted). 
Although chronic myelogenous leukemia (CML) is believed to arise 
as a consequence of clonal expansion of defective primitive 
hematopoietic progenitors, tire role of hematopoietic stem cell self- 
renewal genes, such asb-catenin, in expansion of the leukemic smm 
ceil pool has not been fully elucidated. Using confocai fluorescence 
microscopy (Zeiss LSM), intranuclear and cytoplasmic b-catenin 
expression was found to be elevated in chronic myelogenous 
leukemic ompared with normal bone marrow mononuclear cells 
and isotype controls. Five colour FACS analysis demonstrated a 
marked expansion of myeloid progenitors in CML samples corn 
pared with normal bone marrow or peripheral blood but equivalent 
numbers of hematopoietic stem cells. Notably, b-catenin expression 
was found to be elevated in CML compared with normal myeloid 
progenitors while b catenin expression was similar in CML and 
normal HSC. Moreover, because b-catenin induced activation of 
stem cell self-renewal has been shown to be mediated by binding of 
b catenin to the transcription factor - LEF/TCF, normal and CML 
HSC and myeloid progenitors were transduced with a lentiviral 
LEF /TCF  GFP vector to assay for intranuclear binding of b- 
catenin to its downstream target. Although normal nd CML HSC 
displayed similar LEF /TCF  levels after 7 to 10 days in culture, 
CML myeloid progenitors demonstrated greater GFP expression 
than their normal counterparts indicative of increased nuclear 
translocation of b-catenin. These experiments suggest that activa- 
tion of the leVnt signaling pathway through over-expression f acti- 
vated b-catenin in myeloid progenitors may enhance their leukemic 
potential perhaps as a result of reacquisition ofself-renewal capacity. 
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INFLUENZA INFECTIONS AFTER STEH CELL TRANSPLANTATION (SCT): 
RISK FACTORS, HORTALITY AND THE EFFECT OF ANTIVIRAL THERAPY 
Nichols, ~'~G.; 'l~thvie, ILA.; Corey, L.; Boeckh, M. P'rogram iJ~ llzfi'c- 
tiOHS Disem'es, Fred HutchiJ~son Cm~cer Research Center, Seattle, ~f~4. 
Background: Community-acquired respiratory viruses such as 
influenza virus (FLU) arc thought o be major causes of nmrbidity 
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